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Accurate detection of brain lesions in multiple sclerosis 
(MS) patients is important for diagnosis and measuring 
therapeutic response. In clinical practice, lesion load is 
often visually inspected or quantified by manual or semi-
automated segmentation of Magnetic Resonance Images 
(MRI), which is time-consuming, costly, and associated 
with large inter- and intra-observer variability. We propose 
an automated lesion segmentation method, with high 
reliability and accuracy. In this approach, 2D or 3D 
T1-weighted and FLAIR MR images are used to classify the 
brain into GM, WM and CSF. In addition, by using a healthy 
brain atlas, MS lesions are detected as an outlier to the 
normal brain. The method is evaluated on the brainWeb’s 
MS simulated dataset. For evaluation, three types of MS 
patients are considered, namely, mild, moderate and severe. 
In case of mild patient, the average overlapping of the lesion 
segmentation with the ground truth is 55.48%, 85.07% in 
moderate and 83.67% in severe. The average lesion volume 
difference between the segmentation and the ground truth in 
the mild case is 3.41%, 0.68% in the moderate and 2.19% 
in the severe. As a result, the number and volume of brain 
lesions is measured and can be followed-up in clinical 
practice. In addition, the number and volume of the brain 
lesions is quantified for different brain regions, such as the 
frontal lobe, midbrain, parietal lobe, etc. Clinicians can then 
relate lesion volume changes as well as the number of new 
lesions in different brain regions with changes in the clinical 
situation.
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Objectives: Chronic Lymphocytic Inflammation with 
Pontine Perivascular Enhancement Responsive to Steroids 
(CLIPPERS) is an inflammatory CNS disorder characterized 
by 
1) sub-acute onset of cerebellar and brainstem symptoms, 
2) mainly peripontine contrast-enhancing perivascular 
lesions with a “salt-and-pepper” appearance on MRI, and 
3) angiocentric, predominantly T-lymphocytic infiltration 
as revealed by brain biopsy. 
Neuroinfectious diseases, CNS lymphoma and, of note, 
neurosarcoidosis must be excluded. As CLIPPERS has been 
described as recently as 2010, many patients may have been 
misdiagnosed in the past. 
Methods: We searched the medical records from the 
Department of Neurology at Rigshospitalet, Copenhagen 
University Hospital, for patients discharged between 1999-
2013 with a diagnosis of “sarcoidosis with other localization” 
(D86), “other acute disseminating demyelination” (G36), 
“other demyelinating disease in the CNS” (G37) or 
“encephalitis, myelitis or encephalomyelitis” (G04.9). 
Results: Of 206 identified patients, 24 had been examined 
by brain biopsy and were included for further evaluation. 
Following clinical, neuroradiological and neuropathological 
review, 3 patients (12.5%) were reclassified as having 
CLIPPERS. To the authors’ knowledge these are the first 
reported Scandinavian cases of CLIPPERS; median long-
term follow-up was 75 months. 
Conclusions: The present results suggest that clinical 
review of patients previously diagnosed as neurosarcoidosis 
or unspecified inflammatory demyelinating CNS disease 
might increase the detection rate of CLIPPERS.
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